Martina Reberšek (Avtor), Nežka Hribernik (Avtor)

Povzetek

Slabost in bruhanje ostajata kljub velikemu napredku najpogostejša neželena učinka sistemskega zdravljenja, ki bistveno zmanjšata bolnikovo kvaliteto življenja in zmanjšata njegovo komplianco za nadaljevanje sistemskega zdravljenja. Priporočila za preprečevanje in zdravljenje slabosti in bruhanja zaradi zdravljenja s citostatiki so bila objavljena leta 2003 v reviji Onkologija. S tem prispevkom dopolnjujemo priporočila za obravnavo slabosti in bruhanja z novostmi, ki so bila objavljena v NCCN smernicah leta 2014 in MASCC in ESMO leta 2010 (1,2).

Ključne besede

slabost;bruhanje;onkološki bolniki;sistemsko zdravljenje;

Podatki

Jezik: Slovenski jezik
Leto izida:
Tipologija: 1.04 - Strokovni članek
Organizacija: OI - Onkološki inštitut Ljubljana
UDK: 616-006
COBISS: 1964155 Povezava se bo odprla v novem oknu
ISSN: 1408-1741
Matična publikacija: Onkologija
Št. ogledov: 2668
Št. prenosov: 586
Ocena: 0 (0 glasov)
Metapodatki: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Ostali podatki

Sekundarni jezik: Angleški jezik
Sekundarni naslov: Recommendations for prevention and treatment of nausea and vomiting in systemic oncology treatment
Sekundarni povzetek: In spite of great advancement, nausea and vomiting remain the most common undesirable effects of systemic cancer treatment, which substantially lower the patients’ quality of life and reduce their compliance to continue systemic treatment. Recommendations for prevention and treatment of nausea and vomiting resulting from cytostatic treatment were published in 2003 in Oncology magazine. This article complements the recommendations for treatment of nausea and vomiting with new developments, which were published in the NCCN guidelines in 2014 and MASCC and ESMO in 2010 (1, 2). We present our method for treating dysphagia with the help of intraluminal oesophageal stents. In our practice, the intraluminal oesophageal stent has proven to be a very effective and the most patient-friendly method for optimal delivery of nutrients before and during neoadjuvant therapy. There are few complications, and insertions do not have a negative impact on the perioperative outcomes.
URN: URN:NBN:SI
Strani: str. 105-107, 119
Letnik: ǂLetn. ǂ18
Zvezek: ǂšt. ǂ2
Čas izdaje: dec. 2014
ID: 10957701